GGrantIndex
← Leaderboards

Shannon L Stott

Massachusetts General Hospital

$3,615,955
Attributed
$6,952,034
Total exposure
5
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.5M · FY201825
$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$6,952,034 · 5

By mechanism

R01$4,250,199 · 3
U18$1,998,964 · 1
U01$702,871 · 1

Most similar at Massachusetts General Hospital

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Laboratories

Research focus

LaboratoriesSamplingTechnologyMicrofluidic MicrochipsTranslatingBloodLiquid BiopsyParticleCohortTreatment ResponseMicrofluidic TechnologyMalignant NeoplasmsResponseTissuesTumorMicrofluidicsDiagnosisCellsBlood TestsExtracellular VesiclesProteinsGenomicsData SetSignal Transduction

Grant awards (13)

Validating the hybrid epithelial/mesenchymal state as a biomarker of treatment response and outcomes in head and neck cancer$702,871
U01 · FY2025 · DE
Clinical Translation of a Large Oncosome-Based Prostate Cancer Blood Test$480,986
R01 · FY2025 · CA
Clinical Translation of a Large Oncosome-Based Prostate Cancer Blood Test$135,000
R01 · FY2025 · CA
Precision imaging of the spatial regulators of the hybrid epithelial/mesenchymal state in head and neck cancer$701,699
R01 · FY2024 · DE · contact PI
Clinical Translation of a Large Oncosome-Based Prostate Cancer Blood Test$649,486
R01 · FY2024 · CA
Benchmarking the Sensitivity and Specificity of the Herringbone Microfluidic Device for Rare Particle Capture$26,857
R01 · FY2023 · CA · contact PI
Microfluidic Isolation and Characterization of SARS-CoV-2 and Virus Related Exosomes$999,104
U18 · FY2022 · TR · contact PI
A microfluidic blood-based test to monitor treatment response in glioblastoma$458,136
R01 · FY2022 · CA · contact PI
Microfluidic Isolation and Characterization of SARS-CoV-2 and Virus Related Exosomes$999,860
U18 · FY2021 · TR · contact PI
A microfluidic blood-based test to monitor treatment response in glioblastoma$454,640
R01 · FY2021 · CA · contact PI
A microfluidic blood-based test to monitor treatment response in glioblastoma$451,144
R01 · FY2020 · CA · contact PI
A microfluidic blood-based test to monitor treatment response in glioblastoma$437,611
R01 · FY2019 · CA · contact PI
A microfluidic blood-based test to monitor treatment response in glioblastoma$454,640
R01 · FY2018 · CA · contact PI